Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon therapy for chronic myelogenous leukemia]

A Shibata1, S Hashimoto

  • 1First Dept. of Internal Medicine, Niigata University School of Medicine, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 1, 1993
PubMed
Summary

Interferon alpha (IFN alpha) showed promise in treating chronic myelogenous leukemia (CML) by inducing hematological remission. Further research is needed to understand its mechanisms and optimize combination therapies for minimizing the Ph1 clone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Entner-Doudoroff pathway in Escherichia coli is induced for oxidative glucose metabolism via pyrroloquinoline quinone-dependent glucose dehydrogenase.

Applied and environmental microbiology·1992
Same author

Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·1992
Same author

Location and dynamics of alpha-tocopherol in model phospholipid membranes with different charges.

Chemistry and physics of lipids·1992
Same author

Immunohistochemical characterization of infiltrating mononuclear cells in the rat heart with experimental autoimmune giant cell myocarditis.

Clinical and experimental immunology·1992
Same author

Successful radiofrequency current catheter ablation of sustained ventricular tachycardia.

Pacing and clinical electrophysiology : PACE·1992
Same author

In vitro purging of clonogenic leukemic cells from human bone marrow by heat: simulation experiments for autologous bone marrow transplantation.

Leukemia research·1992

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Context:

  • Interferon alpha (IFN alpha) has been investigated for chronic myelogenous leukemia (CML) treatment since 1983.
  • Initial studies by Talpaz et al. indicated significant hematological remission rates.
  • The precise mechanisms of IFN alpha's efficacy in CML were not fully understood.

Purpose:

  • To review the historical use and potential mechanisms of Interferon alpha in CML treatment.
  • To explore the role of T cell immunity in IFN alpha's anti-leukemic effects.
  • To discuss the limitations and future directions for IFN alpha-based CML therapies.

Summary:

  • Interferon alpha (IFN alpha) treatment demonstrated the potential for high hematological remission in chronic myelogenous leukemia (CML).

Related Experiment Videos

  • Its therapeutic effects may involve cell surface membrane interactions and the induction of inhibitory proteins.
  • IFN alpha appears to modulate T cell immunity, potentially inhibiting Philadelphia chromosome-positive (Ph1) cells.

    • Impact:

    • IFN alpha therapy, despite limitations in achieving complete Ph1-negative hematopoiesis, offers a therapeutic avenue for CML.
    • Intensive treatment strategies combining IFN alpha with other therapies are crucial for minimizing the Ph1 clone.
    • Understanding IFN alpha's immunomodulatory effects could lead to improved CML treatment protocols.